The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-85
SponsorBeijing Suncadia Pharmaceuticals Co., Ltd

About this trial

This trial will evaluate the efficacy and safety of HRS-4029 compared with placebo in participants with acute ischemic stroke (AIS).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Fully understand and voluntarily participate in this trial, and sign the informed consent form (the informed consent form can be signed voluntarily by the participant or their legal representative).

Stroke onset within 3 hours prior to screening, and expected to receive study drug administration within 3 hours after stroke onset.

Clinical diagnosis of acute ischemic stroke (AIS).

Modified Rankin Scale (mRS) score ≤1 prior to stroke onset.

Disqualifiers

Intracranial hemorrhagic diseases, including but not limited to hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc..

Severe impairment of consciousness: NIHSS Item 1a (Level of Consciousness) score ≥ 2.

Concurrent other neurological/psychiatric disorders (e.g., Parkinsonism, epilepsy, severe cognitive impairment, severe depression, etc.) that render the patient uncooperative or unwilling to cooperate with physical examination, or that may affect the evaluation of outcomes.

Persistent systolic blood pressure ≥ 200 mmHg and/or diastolic blood pressure ≥ 110 mmHg following active antihypertensive treatment.

Trial design

Design model

Parallel

Treatments tested in this trial

  • HRS-4029

    Drug

    HRS-4029

  • Placebo

    Drug

    Placebo

Treatment groups

340 Participants
are divided into 4 treatment groups
Group A: HRS-4029 low doseExperimental treatment 1 intervention
Group B: HRS-4029 medium doseExperimental treatment 1 intervention
Group C: HRS-4029 high doseExperimental treatment 1 intervention
Group D: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

The Proportion of Participants With Modified Rankin Scale (mRS) Score ≤ 2

The modified Rankin score (mRS) is a 6-point scale commonly used to assess disability due to stroke, with higher values indicating worse outcomes. 0 = No symptoms; 1 = No significant disability; 2 = Slight disability; 3 = Moderate disability; 4 = Moderately severe disability; 5 = Severe disability; 6 = Death.

Time frame
Day 90

Secondary outcomes

1

The Infarct Volume

Time frame
24 hours
2

The Proportion of Participants With Improvement of 4 or more points, or return to the National Institutes of Health Stroke Scale (NIHSS) total score of 0 or 1

The National Institutes of Health Stroke Score (NIHSS) is a 15-item scale that measures neurological deficit in acute stroke patients. Each item is ranked using a 3-, 4-, or 5-point scale, including allowances for items that cannot be scored due to the patient's condition, with higher scores indicating more severe deficit. Total scores range from 0-42, with higher scores indicating more severe deficits.

Time frame
Day 10
3

The Proportion of Participants With Modified Rankin Scale (mRS) score ≤ 1

Time frame
Day 90
4

Ordinal Modified Rankin Scale (mRS) Score

Time frame
Day 90

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: